Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin

Aliment Pharmacol Ther 31, 1346–1353 Summary Background  The optimal dose of ribavirin to be used in combination with Peg‐IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been established. Aim  To explore the relationship between starting ribavirin doses, expressed as mg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2010-06, Vol.31 (12), p.1346-1353
Hauptverfasser: MANGIA, A., DALGARD, O., MINERVA, N., VERBAAN, H., BACCA, D., RING‐LARSEN, H., COPETTI, M., CARRETTA, V., PIAZZOLLA, V., COZZOLONGO, R., MOTTOLA, L., ANDRIULLI, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!